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In environments with low HIV infection rates, acute pancreatitis is 
common in HIV-positive individuals. The causes of pancreatitis and 
the outcomes in this setting vary,[1] with reports of acute pancreatitis 
being more prevalent and having poorer outcomes in HIV-infected 
patients than in patients without HIV infection.[1,2] The studies in 
low-incidence settings were conducted during the early period of the 
use of highly active antiretroviral therapy (HAART) (the late 1990s) 
and the following decade, which saw the introduction of new agents 
and a decline in mortality associated with HIV infection. There is 
little information on the incidence and outcome of acute pancreatitis 
over an extended period during the HAART era.
Objective
To examine the prevalence and outcome of acute pancreatitis 
associated with HIV infection in a cohort of patients with acute 
pancreatitis admitted to a regional hospital service with a high 
prevalence of HIV infection during May 2001 - November 2010, a 
period that covers the introduction and expansion of HAART in the 
management of HIV infection in South Africa (SA).
Methods
All patients admitted to the adult surgical wards at Addington 
Hospital, Durban, SA, with a diagnosis of acute pancreatitis were 
included in a prospective dataset. Data from May 2001 to November 
2010 were retrospectively analysed. The Glasgow criteria (score ≥3)
and organ dysfunction at presentation were used to assess prognosis. 
Complications related to acute pancreatitis and mortality were noted. 
HIV infection was sought by medical history. A diagnosis of acute 
pancreatitis was based on typical clinical symptoms (epigastric pain, 
nausea, vomiting) and a serum amylase level ≥3 times the upper limit 
of normal (25 - 125 IU/L) or a urinary amylase level >760 IU/L.
A contrast-enhanced computed tomography (CT) scan of the 
pancreas was performed in patients with predicted severe disease 
and in those with persistent symptoms at the end of the first week 
after admission. The CT scan was used to determine the presence of 
local complications of acute pancreatitis such as pancreatic necrosis, 
peripancreatic fluid collections and pancreatic ascites, and to confirm 
the diagnosis of pancreatitis when this was doubtful. The frequency 
of sepsis was analysed in HIV-positive and HIV-negative patients.
Statistical analysis
Descriptive statistics were used to determine the characteristics 
of the cohort. Continuous variables were expressed as means and 
ranges and categorical variables as percentages and proportions. 
Continuous variables were compared using the t-test and categorical 
variables using the χ2 test and Fisher’s exact test. Statistical analysis 
was conducted using SPSS version 2.0 (IBM, USA). Results were 
considered statistically significant at p<0.05.
Ethical approval
Ethical approval was obtained from the local ethics committees of 
the Department of Health and the University of KwaZulu-Natal (ref. 
no. BE222/1).
Results
There were 627 admissions of patients with acute pancreatitis during 
the period May 2001 - November 2010, and 106 patients (16.9%) 
were HIV-positive at presentation. The demographic details are set 
out in Table 1. Of the HIV-positive patients, most were female (65.1%) 
and black African (92.5%). The duration of symptoms ranged from 
1 to 30  days, with a mean of 9.2 days. The CD4 count was known 
in 82  patients (77.3%) with a mean of 220 cells/µL (range 8 - 697); 
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51/82 patients (62.1%) had a CD4 count <200 cells/µL. The body mass 
index was calculated in 81 patients, with a mean of 26 kg/m2 (range 
16 - 64).
The serum amylase level was used to confirm acute pancreatitis in 
50 patients, with a mean of 1 569 IU/L (range 375 - 5 769) and urinary 
amylase in 56 patients, with a mean of 4 083 IU/L (range 934 - 36 856). 
Of the 20 HIV-positive patients (18.9%) with a serum amylase level 
<1 000 U/L, 7 had evidence of acute pancreatitis on the CT scan. The 
prevalence of the common causes of pancreatitis differed between the 
HIV-positive and HIV-negative groups (Table 1). Alcohol was a less 
frequent cause in the HIV-positive group than in those who were HIV-
negative (p=0.0001), whereas the frequency of gallstones was similar 
(p=0.1741). Sixty-four (60.4%) of the HIV-positive patients were on 
HAART (Table 2), and in 38 cases (59.4%) this was the only possible 
cause of the pancreatitis. The Glasgow criteria predicted intensive 
care admission, complications and mortality with similar accuracy in 
the HIV-positive and HIV-negative patients. In 44 patients, imaging 
by CT scan (n=23) and ultrasound (n=21) showed a normal pancreas 
(Balthazar A), while in 46 patients, a CT scan (n=39) and ultrasound 
(n=7) showed features of acute pancreatitis.
In 13 HIV-positive patients (12.3%), the CT scan and a raised 
erythrocyte sedimentation rate showed the pancreatitis to be 
associated with abdominal tuberculosis. Of the HIV-positive patients, 
20 (18.9%) had septic complications (6 chest infections, 5 central line 
sepsis, 3 septicaemia and 3 infections of necrotic pancreas). Two of 
the 3 patients with infected necrosis were successfully managed non-
operatively, and the other had a methicillin-resistant Staphylococcus 
aureus infection and died 2 weeks after admission. Eight patients 
presented with lactic acidosis, of whom 3 died within 1 week of 
admission. The rate of sepsis was significantly higher in the HIV-
positive patients than in those who were HIV-negative (Table 1).
Six HIV-positive patients (5.7%) had malignancies. These were 
four lymphomas in the head of the pancreas diagnosed by endoscopic 
ultrasound and aspiration, a pararenal lymphoma and a renal cell 
carcinoma diagnosed by CT scan and percutaneous aspiration. One 
of these patients died of disseminated disease at 2 weeks without 
features of pancreatic inflammation on a CT scan. No malignancies 
were found in the patients without HIV infection.
Four patients developed pseudocysts, which were managed expec-
tantly. Six HIV-positive patients (5.7%) died, of whom 3 (2 on 
HAART) had CD4 counts <200 cells/µL.
Discussion
This and previous studies at Addington Hospital have demonstrated 
an increase in the prevalence of HIV in association with pancreatitis, 
from 5% (2001 - 2006)[3] and 10% (2001 - 2008)[4] to 16.9% in the pres-
ent study (Fig. 1). An increasing incidence from 2.6 events per 1 000 
person-years for the period 1996 - 2000 to 5.1 events per 1 000 person-
years for 2001 - 2006 (p=0.0014) was reported by another group.[5] The 
increase in the prevalence of HIV infection in our study was associated 
with an increase in gallstone-related pancreatitis (Fig. 1).
Table 1. Characteristics of HIV-positive and HIV-negative patients (N=627)
HIV-positive HIV-negative p-value
Total patients, N (%) 106 (16.9) 521 (83.1)
Males/females, n (%) 37 (34.9):69 (65.1) 383 (73.6):138 (26.5) 0.000
Age (yr), mean (range) 36 (12 - 60) 40 (12 - 89) 0.005
Duration of symptoms (d), mean (range) 9.2 (1 - 30) 2 (1 - 14) 0.000
Body mass index (kg/m2), mean (range) 26 (16 - 64) 25.4 (16 - 59) 0.76
Aetiology, n (%)
Alcohol 26 (24.5) 356 (68.3) 0.0001
Gallstones 25 (23.6) 93 (17.9) 0.1741
Malignancy 6 (5.7) 0 0.0001
Ethnic group, n (%)
Black African 97 (91.5) 226 (43.4) 0.000
Mixed race 3 (2.5) 41 (7.9) 0.091
Indian 6 (5.7) 232 (44.6) 0.0001
White 0 22 (4.2) 0.036
Outcomes
Glasgow ≥3, n (%) 19 (17.9) 98 (18.8) 1.00
Organ failure, n (%) 10 (9.4) 51 (9.8) 0.961
Hospital stay (d), mean (range) 11.5 (1 - 44) 10.2 (1 - 123) 0.002
Necrosis pancreas, n (%) 16 (15.1) 47 (9.0) 0.074
Sepsis, n (%) 20 (18.9) 50 (9.6) 0.009
Complications, n (%) 19 (17.9) 108 (20.7) 0.54
Mortality, n (%) 6 (5.7) 37 (7.1) 0.611
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Fig. 1. Trends in aetiology, hospital stay and mortality in all patients with 
pancreatitis (N=627).
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The majority of our patients with HIV-related pancreatitis were 
black African and female. Another study found more males (51.8%) 
and more African Americans (88.2%) with HIV-related pancreatitis. [5] 
The mean ages of 35 and 38 years for females and males, respectively, 
is comparable to the 36, 36.1 and 37.4 years reported in previous 
studies.[5-7] In a previous report, HIV-positive patients with acute 
pancreatitis were of similar age to those without pancreatitis.[6]
The association of lower CD4 counts with pancreatitis is unclear. 
In a previous study, there was a significant negative correlation 
between serum pancreatic enzyme levels and the number of CD4 
lymphocytes.[8] A higher baseline CD4 cell count was associated 
with a decreased risk of pancreatitis.[9] In our study, 51/82 patients 
(62.1%) had CD4 counts <200 cells/µL, whereas in other studies 
the CD4 counts were <200 cells/µL in 57.5%,[5] 32.6%,[6] 63%[7] and 
89% of patients.[10] In a previous report,[8] it was also demonstrated 
that patients with asymptomatic HIV infection or a CD4 cell count 
>500  cells/µL did not develop asymptomatic hyperamylasaemia or 
acute pancreatitis over a 1-year period.
The aetiology of acute pancreatitis in the setting of HIV 
infection also varies, and may include both causes common in 
HIV-negative individuals and HIV-specific causes that include 
medications, opportunistic infections and tumours.[1] There is also 
a report of acute pancreatitis during primary HIV infection.[11] 
In a previous study, pancreatitis was associated with gallstones, 
intravenous drug abuse, pentamidine intake, and Pneumocystis 
jiro veci and Mycobacterium avium-intracellulare infections.[8] Acute 
pancreatitis is also a complication of nucleoside reverse transcriptase 
inhibitors (didanosine, stavudine). The combination of didanosine 
and stavudine was associated with the highest risk.[12] In another 
study, the crude incidence of pancreatitis ranged from 0.18 cases 
per 100 person-years on therapy with zidovudine to 6.25 cases per 
100  person-years for didanosine plus hydroxyurea.[13] In a further 
report, there was no evidence of an association of pancreatitis with 
exposure to didanosine, stavudine or any other HAART regimen.[9] 
There was a similar finding in another report without an association 
with a particular drug regimen.[14] The HAART medications used by 
the patients in this study are listed in Table 2.
A postmortem study of the pancreases of asymptomatic indivi-
duals with AIDS and normal antemortem ultrasound scans of the 
pancreas and normal serum amylase levels revealed mycobacteriosis 
(22%), toxoplasmosis (13%), cytomegalovirus (9%), P. jiroveci (9%) 
and HIV p24 (22%) antigens in macrophage cytoplasm in the 
pancreas. [15] Opportunistic infections of the pancreas have been 
reported in postmortem studies, but there is little information on the 
prevalence or diagnostic modalities appropriate for the antemortem 
environment. No patient in our cohort was diagnosed with 
opportunistic infections before death, and postmortem assessments 
were not performed. HAART, tuberculosis and malignancy were 
more frequent in HIV-positive patients (Table 3). In a previous 
report, drugs, alcohol, hypertriglyceridaemia and opportunistic 
infections were the most common aetiological associations,[6] and in 
another, 46% of cases were associated with medication and 26% had 
an idiopathic aetiology.[7]
 Results reported on the accuracy of severity assessment indices 
are conflicting. In two studies, the Ranson and Glasgow criteria were 
found to be of poor prognostic value and the Apache II score a better 
predictor of an unfavourable outcome.[2,7] However, the best overall 
accuracy of the Apache II system as a predictive tool (75%) leaves a 
lot to be desired.[7] In sharp contrast, another report demonstrated 
Ranson’s criteria to be of similar value in predicting a poor outcome 
as was found in other non-HIV-related series.[16] Lack of consensus 
on severity indices is added to by Parithivel et al.’s[10] report, in which 
89% of patients had CD4 counts <200 cells/µL. They found that the 
commonly used predictors of severe disease were unhelpful because 
of altered hepatic and renal function and low white cell counts in 
HIV-infected patients. In our study, the frequencies of a Glasgow 
score of ≥3, organ failure and mortality were found to be similar in 
the HIV-positive and HIV-negative groups.
The mortality rate of 5.7% in this study is similar to the rate of 
5.9% reported by Smith et al.,[9] but is much lower than the 32% 
reported a decade earlier in a study that had a significant number of 
patients with AIDS in the cohort.[10]
Conclusions
In our setting, acute pancreatitis associated with HIV infection was 
most common in females and in black African patients. The serum 
amylase level was elevated for prolonged periods and may be used to 
aid diagnosis after 72 hours of symptoms. Drug-related pancreatitis 
was more frequent and alcohol as a cause less frequent in HIV-
related pancreatitis. Malignancy in this cohort was associated with 
HIV infection. Although pancreatic necrosis was more common 
in HIV-related pancreatitis, mortality was similar. However, it was 
Table 2. Highly active antiretroviral therapy regimens (N=64)
Patients, n
Stavudine (NRTI)/lamivudine (NRTI)/efavirenz (NNRTI) 56
Stavudine (NRTI)/lamivudine (NRTI)/nevirapine (NNRTI) 4
Zidovudine (NRTI)/lamivudine (NRTI)/efavirenz (NNRTI) 1
Stavudine (NRTI)/nevirapine (NNRTI)/didanosine (NRTI) 1
Lamivudine (NRTI)/efavirenz (NNRTI)/tenofovir (PI) 1
Lamivudine (NRTI)/didanosine (NRTI)/nevirapine (NNRTI) 1
NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor.
Table 3. Cause of pancreatitis and spectrum of CD4 counts 
and tumours in HIV-infected patients (N=106)
n (%)
Cause of pancreatitis
Alcohol 26 (24.5)
Gallstones 25 (23.6)
HAART 38 (35.8)
HIV only 11 (10.4)
CD4 count (cells/µL) (N=82)
≥200 31 (38.3)
<200 51 (62.1)
Malignancy
Lymphoma head of pancreas 4 (3.8)
Pararenal lymphoma 1 (0.9)
Renal cell carcinoma 1 (0.9)
HAART = highly active antiretroviral therapy.
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not possible to draw firm conclusions from this cohort, as not all 
patients admitted with pancreatitis were tested for HIV infection and 
there may have been a bias towards those with more advanced HIV 
infection. A prospective study with routine testing of all admissions 
with acute pancreatitis is required to ascertain whether these trends 
are applicable to all with HIV-related pancreatitis.
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